Long-term therapy with long-acting octreotide (Sandostatin-LAR® ) for the management of acromegaly-Reference-Cited by-同舟云学术

Long-term therapy with long-acting octreotide (Sandostatin-LAR® ) for the management of acromegaly

Published:1998-03 Issue:3 Volume:48 Page:311-316
ISSN:0300-0664
Container-title:Clinical Endocrinology
language:en
Short-container-title:Clinical Endocrinology

Author:

Davies Peter H.,Stewart Susan E.,Lancranjan Ioana,Sheppard Michael C.,Stewart Paul M.

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism,Endocrinology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2265.1998.00389.x/fullpdf

Reference28 articles.

1. An audit of outcome of treatment in acromegaly;Bates;Quarterly Journal of Medicine,1993

2. Treatment of acromegaly by the slow-release formulation of a new somatostatin analogue, lanreotide;Boucekkine;Annales d'Endocrinologie (Paris),1994

3. Intramuscular injections of slow-release lanreotide (BIM 230014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995);Caron;European Journal of Endocrinology,1995

4. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients;Christensen;Clinical Endocrinology (Oxford),1987

5. Surgical management of acromegaly;Fahlbusch;Endocrinology and Metabolism Clinics of North America,1992

Cited by 123 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Delivery Systems;Kirk-Othmer Encyclopedia of Chemical Technology;2023-09-29

2. Development of membrane‐active peptide therapeutics in oncology;Journal of Peptide Science;2023-02-11

3. The industrial design, translation, and development strategies for long-acting peptide delivery;Expert Opinion on Drug Delivery;2022-07-21

4. Clinically established biodegradable long acting injectables: An industry perspective;Advanced Drug Delivery Reviews;2020-12

5. Long-Acting Injectables: Current Perspectives and Future Promise;Critical Reviews™ in Therapeutic Drug Carrier Systems;2019